These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 30649751)

  • 1. Safety and Tolerability of Phosphatidylinositol-3-Kinase (PI3K) Inhibitors in Oncology.
    Curigliano G; Shah RR
    Drug Saf; 2019 Feb; 42(2):247-262. PubMed ID: 30649751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of adverse events associated with idelalisib treatment: expert panel opinion.
    Coutré SE; Barrientos JC; Brown JR; de Vos S; Furman RR; Keating MJ; Li D; O'Brien SM; Pagel JM; Poleski MH; Sharman JP; Yao NS; Zelenetz AD
    Leuk Lymphoma; 2015; 56(10):2779-86. PubMed ID: 25726955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
    Greenwell IB; Flowers CR; Blum KA; Cohen JB
    Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K Inhibitors: Understanding Toxicity Mechanisms and Management.
    Greenwell IB; Ip A; Cohen JB
    Oncology (Williston Park); 2017 Nov; 31(11):821-8. PubMed ID: 29179250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis.
    Zhang Y; Xu X; Yang K; Wang S; Zhang T; Hui F; Zheng F; Geng H; Xu C; Xun F; Xu Z; Wang C; Hou S; Song A; Ren T; Zhao Q
    Eur J Pharmacol; 2024 Nov; 983():176952. PubMed ID: 39216745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
    Fruman DA; Rommel C
    Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
    Burger JA; Okkenhaug K
    Nat Rev Clin Oncol; 2014 Apr; 11(4):184-6. PubMed ID: 24642682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.
    Hanlon A; Brander DM
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):346-356. PubMed ID: 33275709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Idelalisib in the management of lymphoma.
    Cheah CY; Fowler NH
    Blood; 2016 Jul; 128(3):331-6. PubMed ID: 27252232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idelalisib.
    Zirlik K; Veelken H
    Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting PI3 kinase in cancer.
    Bauer TM; Patel MR; Infante JR
    Pharmacol Ther; 2015 Feb; 146():53-60. PubMed ID: 25240910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the PI3K pathway in cancer: are we making headway?
    Janku F; Yap TA; Meric-Bernstam F
    Nat Rev Clin Oncol; 2018 May; 15(5):273-291. PubMed ID: 29508857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
    Smith SM; Pitcher BN; Jung SH; Bartlett NL; Wagner-Johnston N; Park SI; Richards KL; Cashen AF; Jaslowski A; Smith SE; Cheson BD; Hsi E; Leonard JP
    Lancet Haematol; 2017 Apr; 4(4):e176-e182. PubMed ID: 28314699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure and ligand-based design of mTOR and PI3-kinase inhibitors leading to the clinical candidates VS-5584 (SB2343) and SB2602.
    Poulsen A; Nagaraj H; Lee A; Blanchard S; Soh CK; Chen D; Wang H; Hart S; Goh KC; Dymock B; Williams M
    J Chem Inf Model; 2014 Nov; 54(11):3238-50. PubMed ID: 25317974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma.
    Yang Q; Chen LS; Ha MJ; Do KA; Neelapu SS; Gandhi V
    Clin Cancer Res; 2017 Jan; 23(1):181-192. PubMed ID: 27342398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAL-101: a phosphatidylinositol-3-kinase p110-delta inhibitor for the treatment of lymphoid malignancies.
    Castillo JJ; Furman M; Winer ES
    Expert Opin Investig Drugs; 2012 Jan; 21(1):15-22. PubMed ID: 22112004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.